Fatty Liver

Fatty liver, also known as fatty liver disease (FLD), is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e. abnormal retention of lipids within a cell).

What is Fatty Liver?

Fatty liver is a very common disorder and up to 20 percent of adults and approximately 5 percent of children are affected.

Fatty Liver Pathology

Fatty Liver Diagnosis

Acute Fatty Liver of Pregnancy Treatment

The role of phytochemicals in combating metabolic diseases

This editorial reviews the impact of phytochemicals on metabolic diseases, emphasizing their potential in reducing inflammation and improving health outcomes.

19 Dec 2024

New drug approach shows promise in treating metabolic liver diseases

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in fat metabolism promoted liver health reduced liver fat, inflammation and fibrotic remodeling (connective tissue scarring).

18 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

12 Dec 2024

Two distinct types of fatty liver disease identified

Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease - a liver-specific type and a systemic type that affects other organs and tissues.

10 Dec 2024

Tea, apples, and chocolate proven to support liver health

A flavonoid-rich diet, including apples, tea, and dark chocolate, significantly lowers the risk of non-alcoholic fatty liver disease (NAFLD) and improves liver health biomarkers. These findings highlight the potential of dietary flavonoids in combating liver fat accumulation and inflammation.

9 Dec 2024

Two new subtypes of MASH revealed with different risks and outcomes

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population.

9 Dec 2024

New compound HPH-15 offers promising alternative to diabetes medications

Kumamoto University scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marking a significant leap in diabetes treatment innovation.

6 Dec 2024

AI tool detects heart disease in CT scans originally meant for other purposes

With the help of an artificial intelligence (AI) tool, computed tomography (CT) scans taken to look for tumors or bleeding or infections, also revealed calcium buildup in arteries, a sign of worsening cardiovascular disease.

4 Dec 2024

Disrupted sleep-wake rhythms linked to liver disease progression

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles. MASLD (formerly known as non-alcoholic fatty liver disease) is already the most common liver disorder: it affects 30% of adults and between 7% and 14% of children and adolescents, and this prevalence is predicted to rise to more than 55% of adults by 2040.

4 Dec 2024

Scientists uncover coffee's surprising effect on gut microbiota

Scientists reveal that coffee consumption influences gut microbiota composition, with a strong link to the bacterium Lawsonibacter asaccharolyticus, independent of caffeine.

3 Dec 2024

Disrupted sleep patterns identified in patients with metabolic dysfunction-associated steatotic liver disease

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles.

2 Dec 2024

Understanding the pathophysiological relationship between OSA and metabolic syndrome

Cardiovascular diseases remain a leading cause of mortality globally, particularly among individuals with both obstructive sleep apnea (OSA) and metabolic syndrome (MetS).

27 Nov 2024

Mursla Bio's EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-center clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz.

From Mursla Bio 25 Nov 2024